Skip to content
  1. Home
  2. >Test Catalog
  3. >Pharmacogenomics
  4. >Pharmacogenomics Pgx Cardiovascular Panel
Back to catalog

Pharmacogenomics (PGx) Cardiovascular Panel

An 11-gene pharmacogenomic panel for optimizing cardiovascular drugs including anticoagulants, antiarrhythmics, antihypertensives, antiplatelets, beta blockers, and statins, powered by the Helix Exome+® platform.

Turnaround

6-9 days

Turnaround Requery

≤ 5 minutes

Panel Description

Many medications used to treat cardiovascular conditions are impacted by specific variations in known genes. These genetic variations can contribute to medication efficacy and risk for side effects. Pharmacogenomic testing to guide prescribing, paired with clinical monitoring can impact outcomes for patients by reducing the time to therapeutic effect and reducing the risk of side effects.

This panel evaluates 11 genes associated with response to drugs prescribed to treat cardiovascular disease, including anticoagulants, antiarrhythmics, antihypertensives, antiplatelets, beta blockers, and HMG-CoA Reductase Inhibitors (statins). Results from this test may help in predicting treatment efficacy and risk of side effects for these drugs.

View the complete description of this panel
Sample report

Have Questions?

Our team is available Monday through Friday, 9am-5pm Pacific Time.

(844) 211 2070clinicalsupport@helix.com

Indications for Testing

Patients for whom cardiovascular medications are being considered, have been ineffective or caused side effects.

Methodology

This test utilizes next-generation sequencing to determine results for ABCB1, ABCG2, CYP2C cluster, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP4F2, GRK4, SLCO1B1, and VKORC1.

Technical Specifications

Reportable rangeABCB1: rs2032582, rs1128503, rs1045642; ABCG2: rs2231142; CYP2C cluster: rs12777823; CYP2C9: *1-*61; CYP2C19: *1-*19, *22-*26, *28-*39; CYP2D6: *1-*15, *4N, *17-*65, *68-*75, *81, *83-*114; CYP3A4: *1... Technical noteSensitivity may be reduced for the CYP2D6*13 allele.

Genes Tested

ABCB1
ABCG2
CYP2C cluster
CYP2C9
CYP2C19
CYP2D6
CYP3A4
CYP4F2
GRK4
SLCO1B1
VKORC1

Showing 11 of 11 genes in this panel

Other Tests to Consider

Test

Malignant Hyperthermia Susceptibility Panel

3

genes

Test

Pharmacogenomics (PGx) APOE Test

1

gene

Test

Pharmacogenomics (PGx) Fluoropyrimidines DPYD Test

1

gene

Test

Pharmacogenomics (PGx) Level A Panel

16

genes

Important Panel Information

Turnaround time: Typically 7-10 days (standard), Typically < 5 minutes (requery)

Preferred specimen: BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit

Shipping Instructions: Specimens to arrive at Helix within 96 hours of collection at ambient temperature.

This test utilizes next-generation sequencing to determine results for ABCB1, ABCG2, CYP2C cluster, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP4F2, GRK4, SLCO1B1, and VKORC1. These results are used to determine drug considerations for the following drugs: Atorvastatin, Clopidogrel, Flecainide, Fluvastatin, Lovastatin, Metoprolol, Pitavastatin, Pravastatin, Propafenone, Rosuvastatin, Simvastatin, Warfarin.

Additionally, due to lack of sufficient scientific evidence, genetic outcomes are provided without drug considerations for the following drugs: Atenolol, Carvedilol, Digoxin, Losartan, Nebivolol, Propranolol, Quinidine, Timolol.

All detected variants are evaluated according to the Clinical Pharmacogenetics Implementation Consortium (CPIC). Variants are classified based on known, predicted, or possible impact on drug metabolism.